CTx and its commercialisation partner Cancer Research Technology (CRT) are pleased to announce a multimillion dollar licensing deal with MSD, known as Merck in the US and Canada, to develop inhibitors of protein arginine methyltransferase 5 (PRMT5), a promising new group of drugs which have clinical potential in both cancer and non-cancer blood disorders.
One of the largest preclinical deals in Australian history, this highlights the quality and value of Australian cancer research and researchers on the international stage.
Key points of this deal include
- Promising new drugs which have potential clinical applications for both cancer and non-cancer blood disorders affecting millions of people worldwide
- Upfront payment in excess of AUD$21 million and potential payments in excess AUD$0.7 billion
- Majority of revenues will be returned to CTx and its Australian research partners
- Additional funded collaboration between MSD and CTx on blood disorders